Chronic kidney disease and urological disorders: systematic use of uroflowmetry in nephropathic patients.

chronic kidney disease end-stage renal disease max flow rate uroflowmetry urological disorders

Journal

Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 24 01 2018
entrez: 15 6 2019
pubmed: 15 6 2019
medline: 15 6 2019
Statut: epublish

Résumé

Chronic kidney disease (CKD) is a highly prevalent condition. Urologic disorders are known causes of CKD, but often remain undiagnosed and underestimated also for their insidious onset and slow progression. We aimed to evaluate the prevalence of urological unrecognized diseases in CKD patients by uroflowmetry. We enrolled consecutive stable CKD outpatients. The patients carried out two questionnaires, the International Prostate Symptom Score and Incontinence Questionnaire-Short Form, and they also underwent uroflowmetry, evaluating max flow rate ( A total of 83 patients (43 males, mean age of 59.8 ± 13.3 years) were enrolled. Our study showed 28 males and 10 females with a significant reduction of We showed an elevated prevalence of urological diseases in nephropathic patients; therefore, we suggest to include uroflowmetry in CKD patient assessment, considering the non-invasiveness, repeatability and low cost of examination. Uroflowmetry could be used to identify previously unrecognized urological diseases, which may prevent the onset of CKD or progression to end-stage renal disease and reduce the costs of management.

Sections du résumé

BACKGROUND BACKGROUND
Chronic kidney disease (CKD) is a highly prevalent condition. Urologic disorders are known causes of CKD, but often remain undiagnosed and underestimated also for their insidious onset and slow progression. We aimed to evaluate the prevalence of urological unrecognized diseases in CKD patients by uroflowmetry.
METHODS METHODS
We enrolled consecutive stable CKD outpatients. The patients carried out two questionnaires, the International Prostate Symptom Score and Incontinence Questionnaire-Short Form, and they also underwent uroflowmetry, evaluating max flow rate (
RESULTS RESULTS
A total of 83 patients (43 males, mean age of 59.8 ± 13.3 years) were enrolled. Our study showed 28 males and 10 females with a significant reduction of
CONCLUSIONS CONCLUSIONS
We showed an elevated prevalence of urological diseases in nephropathic patients; therefore, we suggest to include uroflowmetry in CKD patient assessment, considering the non-invasiveness, repeatability and low cost of examination. Uroflowmetry could be used to identify previously unrecognized urological diseases, which may prevent the onset of CKD or progression to end-stage renal disease and reduce the costs of management.

Identifiants

pubmed: 31198542
doi: 10.1093/ckj/sfy085
pii: sfy085
pmc: PMC6543956
doi:

Types de publication

Journal Article

Langues

eng

Pagination

414-419

Références

J Urol. 2000 Nov;164(5):1490-3
pubmed: 11025689
BJU Int. 2001 Apr;87(6):581-4
pubmed: 11298062
J Am Soc Nephrol. 2002 Jan;13 Suppl 1:S37-40
pubmed: 11792760
J Urol. 1992 Nov;148(5):1549-57; discussion 1564
pubmed: 1279218
BMJ. 2004 Mar 13;328(7440):634-40
pubmed: 15016698
Neurourol Urodyn. 2004;23(4):322-30
pubmed: 15227649
BJU Int. 2006 Jan;97(1):101-8
pubmed: 16336337
Ann Intern Med. 2006 Aug 15;145(4):247-54
pubmed: 16908915
Nihon Ronen Igakkai Zasshi. 2006 Jul;43(4):498-504
pubmed: 16937943
Rev Urol. 2004;6 Suppl 1:S32-7
pubmed: 16985853
Rev Urol. 2005;7 Suppl 6:S14-21
pubmed: 16986024
Pediatr Nephrol. 2007 Dec;22(12):1999-2009
pubmed: 17310363
BJU Int. 2010 May;105(10):1424-8
pubmed: 19874305
Ther Adv Urol. 2010 Oct;2(5-06):187-94
pubmed: 21789074
G Ital Nefrol. 2011 Jul-Aug;28(4):401-7
pubmed: 21809309
J Urol. 2011 Oct;186(4):1460-6
pubmed: 21855938
Pediatr Nephrol. 2014 May;29(5):779-92
pubmed: 23471475
Diabetes Res Clin Pract. 2015 Jul;109(1):164-9
pubmed: 25979274
Lancet Neurol. 2015 Jul;14(7):720-32
pubmed: 26067125
Korean J Urol. 2015 Dec;56(12):803-10
pubmed: 26682020
J Renal Inj Prev. 2015 Nov 30;4(4):120-6
pubmed: 26693499
Can Urol Assoc J. 2017 Mar-Apr;11(3-4):E83-E87
pubmed: 28360952
J Urol. 1981 Aug;126(2):205-9
pubmed: 7196460
J Urol. 1993 Nov;150(5 Pt 2):1706-8; discussion 1708-9
pubmed: 7692106
Eur Urol. 1997;31(2):129-40
pubmed: 9076454

Auteurs

Silvia Lai (S)

Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy.

Serena Pastore (S)

Department of Obstetrical-Gynecological Sciences and Urologic Sciences, Sapienza University of Rome, Rome, Italy.

Leonardo Piloni (L)

Department of Obstetrical-Gynecological Sciences and Urologic Sciences, Sapienza University of Rome, Rome, Italy.

Marco Mangiulli (M)

Department of Internal Medicine and Medical Specialities, Sapienza University of Rome, Rome, Italy.

Ylenia Esposito (Y)

Department of Internal Medicine and Medical Specialities, Sapienza University of Rome, Rome, Italy.

Federico Pierella (F)

Department of Obstetrical-Gynecological Sciences and Urologic Sciences, Sapienza University of Rome, Rome, Italy.

Alessandro Galani (A)

Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Giovanni Pintus (G)

Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy.

Daniela Mastroluca (D)

Nephrology and Dialysis Unit, Hospital ICOT Latina, Sapienza University of Rome, Rome, Italy.

Hossein Shahabadi (H)

Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.

Mauro Ciccariello (M)

Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.

Stefano Salciccia (S)

Department of Obstetrical-Gynecological Sciences and Urologic Sciences, Sapienza University of Rome, Rome, Italy.

Magnus Von Heland (M)

Department of Obstetrical-Gynecological Sciences and Urologic Sciences, Sapienza University of Rome, Rome, Italy.

Classifications MeSH